Alnylam Pharma (ALNY) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Piper Jaffray Cuts PT on Alnylam (ALNY) by 45%; Keep 'Overweight'
February 12, 2016 8:26 AM ESTPiper Jaffray analyst, Edward Tenthoff, cut his Alnylam Pharmaceuticals (NASDAQ: ALNY) price target to $102 from $184 which still represents 79% upside from current levels. No change to Overweight rating.
Alnylam ended 2015 with cash of $1.28 billion and guided to end 2016 with >$850 million including a $100 million investment in an RNAi manufacturing facility. The company recently completed enrollment of >200 familial amyloidotic polyneuropathy (FAP) patients in the Phase III APOLLO trial setting up top-line data in 2H:17 and a potential launch in 2018. Alnylam is advancing and expanding its... More
